PFA
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shree Ganesh Biotech (India) Ltd reported its unaudited results for the quarter and half year ended September 30, 2025. Revenue from operations fell sharply to Rs. 76.74 lakhs in Q2 FY26 from Rs. 198.40 lakhs in Q2 FY25, a 61% year-on-year drop. For the six-month period, revenue plunged to Rs. 215.10 lakhs from Rs. 554.01 lakhs, also a ~61% decline. Net profit for Q2 collapsed to just Rs. 1.41 lakhs (vs Rs. 32.34 lakhs a year ago, ~96% fall), while H1 PAT stood at Rs. 34.11 lakhs (vs Rs. 56.12 lakhs). A key red flag: cost of materials consumed in H1 FY26 (Rs. 223.72 lakhs) now exceeds revenue from operations, showing the core business is loss-making at the gross level and reliant on other income. The limited review report by Bipin & Co. was clean with no qualifications.
A steep revenue fall and near-zero Q2 profit are significant negatives for the stock. Core operations are unprofitable without support from other income, suggesting weak underlying business health that investors should watch closely.